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Malaria chemoprophylaxis: a proven public health intervention 
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The most notable finding in Luthi and Shlagenhauf’s [1] recent review - that failure to use 
chemoprophylaxis while traveling to malaria-endemic areas is a major risk factor for severe 
malaria and death - is concerning, but not at all surprising. This conclusion should be so 
obvious to the travel medicine community that one might think it did not merit publication at 
all. But clearly it does.
Malaria chemoprophylaxis is an effective means of preventing both morbidity and mortality 
among international travelers to malaria endemic countries. It is a proven public health 
intervention, but unfortunately it is not being utilized sufficiently. There are, of course, 
many reasons for this. Some travelers are not aware of the risk or do not have access to 
appropriate preventive health services. People sometimes forget their medicines, or are non-
adherent to the correct chemoprophylaxis schedule. Repeat and frequent travelers to 
malaria-endemic countries may become complacent about malaria prevention in general or 
may be reluctant to use specific medications for malaria prevention due to side effects they 
might have experienced, perceived, or simply heard about. But the more concerning one is 
the travel medicine health care provider who misses the opportunity to recommend effective 
chemoprophylaxis for the travelers who actually made it in to the clinic seeking such advice. 
Despite clear and consistent evidence that lack of chemoprophylaxis is a risk factor for 
severe malaria and death [1], risk-benefit analyses, special considerations for certain types 
of travelers and settings, promotion of standby emergency medicine, and cost-effectiveness 
calculations are proffered—all of which have the potential to undermine the use of malaria 
chemoprophylaxis [2–5]. Luthi and Schlagenhauf [1] demonstrated that even in instances 
where malaria was not prevented, suboptimal chemoprophylaxis (wrong medications or 
incorrect usage) reduced mortality and the risk of severe disease. The travel medicine 
specialist should be advocating for malaria prevention rather than looking for opportunities 
to avoid prescribing effective chemoprophylaxis. This should include educating the travelers 
on different available options and choosing the chemoprophylaxis that would be most 
suitable for each traveler.
When other proven public health interventions such as vaccination of children are rejected, 
it results in predictable and completely preventable outbreaks [6]. Similarly, the rejection of 
chemoprophylaxis for persons traveling to malaria endemic areas will result in increased 
numbers of cases, severe cases, and deaths. Malaria surveillance reports show us that 
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increased travel to malaria endemic countries correlates with increased numbers of cases in 
travelers [7]. Despite progress being made in malaria control programs worldwide, malaria 
remains a life-threatening, highly-prevalent tropical disease.
We are fortunate to be living in a time where we know how to prevent many diseases with 
proven public health interventions. There are simple things we can all do to prevent illnesses 
and deaths. Wash your hands. Don’t smoke. Use condoms. Cover your cough. Vaccinate 
your children. And if you are traveling to a malaria endemic area, please take your malaria 
chemoprophylaxis.
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